SREBF1 and fatty liver disease: Another study suggested that SCFAs could inhibit hepatic steatosis by activating AMPK and PPAR signaling pathways and down-regulating the expression of genes related to lipid synthesis, such as sterol-regulatory element-binding protein 1 (SREBP-1), FAS, stearoyl-CoA desaturase 1 (SCD1), ACC1, and liver X receptor (LXR) [59].